Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P

Abstract Background: Pathogenetic mechanisms involved in the progression of non-alcoholic fatty liver disease (NAFLD) are complex and multifactorial. We investigated oxidative stress through the measurement of selenoprotein P (SeP) in serum and we explored its relation to metabolic derangements and liver damage in a group of non-diabetic NAFLD subjects. Methods: 57 NAFLD patients underwent a double-tracer oral glucose tolerance test (OGTT). Insulin resistance (IR) components were calculated at baseline as follows: hepatic-IR = (endogenous glucose production*insulin); peripheral-IR = (glucose rate of disappearance(Rd)); adipose-tissue(AT)-IR as Lipo-IR = (glycerol rate of appearance (Ra)*insulin) or AT-IR = (free fatty acids (FFAs)*insulin). The lipid and amino acid (AA) profiles were assessed by gas chromatography–mass spectrometry. SeP levels were measured by enzyme immunosorbent assay. Results: Circulating SeP correlated with insulin (rS = 0.28), FFAs (rS = 0.42), glucose Rd (rS = −0.33) and glycerol Ra (rS = −0.34); consistently, SeP levels correlated with Lipo-IR and AT-IR (rS > 0.4). Among the AA and lipid profiles, SeP inversely correlated with serine (rS = −0.31), glycine (rS = −0.44) and branched chain AA (rS = −0.32), and directly correlated with saturated (rS = 0.41) and monounsaturated FFAs (rS = 0.40). Hepatic steatosis and fibrosis increased in subjects with higher levels of SeP. In multivariable regression analysis, SeP was associated with the degree of hepatic fibrosis (t = 2.4, p = 0.022). Conclusions: SeP levels were associated with an altered metabolic profile and to the degree of hepatic fibrosis, suggesting a role in the pathogenesis of NAFLD.

[1]  SeP is elevated in NAFLD and participates in NAFLD pathogenesis through AMPK/ACC pathway , 2020, Journal of cellular physiology.

[2]  A. Gastaldelli,et al.  Altered Metabolic Profile and Adipocyte Insulin Resistance Mark Severe Liver Fibrosis in Patients with Chronic Liver Disease , 2019, International journal of molecular sciences.

[3]  A. Gastaldelli,et al.  Crosstalk between adipose tissue insulin resistance and liver macrophages in Non Alcoholic Fatty Liver Disease. , 2019, Journal of hepatology.

[4]  H. Misu Identification of hepatokines involved in pathology of type 2 diabetes and obesity. , 2019, Endocrine journal.

[5]  L. Duntas,et al.  Selenoprotein P in Patients with Nonalcoholic Fatty Liver Disease. , 2019, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[6]  U. Nöthlings,et al.  Metabolomics signature associated with circulating serum selenoprotein P levels , 2018, Endocrine.

[7]  A. Gastaldelli,et al.  Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance , 2018, Hepatology.

[8]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[9]  L. Heilbronn,et al.  Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance. , 2017, Obesity research & clinical practice.

[10]  A. Gentilini,et al.  Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.

[11]  E. Bugianesi,et al.  Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. , 2016, Clinics in liver disease.

[12]  E. Bugianesi,et al.  Different Serum Free Fatty Acid Profiles in NAFLD Subjects and Healthy Controls after Oral Fat Load , 2016, International journal of molecular sciences.

[13]  H. Steinbrenner Interference of selenium and selenoproteins with the insulin-regulated carbohydrate and lipid metabolism. , 2013, Free radical biology & medicine.

[14]  H. J. Yoo,et al.  Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease , 2013, Diabetes & metabolism journal.

[15]  M. Capecchi,et al.  Production of Selenoprotein P (Sepp1) by Hepatocytes Is Central to Selenium Homeostasis* , 2012, The Journal of Biological Chemistry.

[16]  E. Brunt,et al.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.

[17]  J. Hardies,et al.  Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease , 2012, Hepatology.

[18]  C. Palmeira,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free radical biology & medicine.

[19]  H. J. Yoo,et al.  Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis. , 2011, The Journal of clinical endocrinology and metabolism.

[20]  M. Honda,et al.  A liver-derived secretory protein, selenoprotein P, causes insulin resistance. , 2010, Cell metabolism.

[21]  G. Marchesini,et al.  Insulin resistance in nonalcoholic fatty liver disease. , 2010, Current pharmaceutical design.

[22]  R. Burk,et al.  Selenoprotein P-expression, functions, and roles in mammals. , 2009, Biochimica et biophysica acta.

[23]  Svati H Shah,et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.

[24]  E. Ferrannini,et al.  Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes , 2007, Clinical pharmacology and therapeutics.

[25]  J. Park [Insulin resistance in non-alcoholic fatty liver disease]. , 2006, The Korean journal of hepatology.

[26]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[27]  E. Çakır,et al.  Systemic Markers of Lipid Peroxidation and Antioxidants in Patients with Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[28]  E. Ferrannini,et al.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms , 2005, Diabetologia.

[29]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[30]  A. Laudanna,et al.  Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline‐deficient diet , 2002, Journal of cellular and molecular medicine.

[31]  J. Köhrle,et al.  Transforming growth factor‐β1 inhibits expression of selenoprotein P in cultured human liver cells , 1999 .

[32]  J. Abel,et al.  Transforming growth factor-beta1 inhibits expression of selenoprotein P in cultured human liver cells. , 1999, FEBS letters.

[33]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.